A startup called AtlasBase has introduced a molecular computing platform built around Thalia, a semiconductor chip designed to synthesize DNA at a scale the company says is unprecedented for commercial use. The pitch is bold: use synthetic DNA not just to archive data, but to compute on it directly, without shuttling information between separate storage and processing systems.
What Thalia Actually Does
Thalia is a CMOS-based chip - meaning it's manufactured using the same complementary metal-oxide-semiconductor processes that underpin most modern electronics. According to AtlasBase, the chip packs 5.6 billion electrochemical synthesis sites onto its surface, each capable of building strands of synthetic DNA. The company describes this as a 700-fold increase in scale compared with prior DNA synthesis chips, a jump it attributes to reusing established semiconductor manufacturing techniques rather than relying on specialized, low-volume fabrication methods common in earlier molecular biology tools.
That manufacturing approach matters because DNA synthesis has historically been slow and expensive, largely confined to lab-scale instruments used in genomics research. By building synthesis sites directly into a chip that can be mass-produced, AtlasBase is wagering it can push molecular technology from a scientific niche toward something resembling industrial IT infrastructure.
Storage and Computation in the Same Medium
The platform's core claim is that it merges two functions - data storage and data processing - inside a single molecular substrate. In conventional computing, data sits in storage (disks, tape, flash) and must be moved to a separate processor to be analyzed. AtlasBase says its system instead performs specialized computation, such as optimization and search problems, directly on DNA strands where the data already resides. The company frames this as particularly suited to workloads that benefit from parallel processing, since vast numbers of DNA molecules can theoretically be manipulated simultaneously.
AtlasBase positions this molecular layer as a complement to, not a replacement for, existing servers and storage arrays. The intended role is long-term data preservation and selected computational tasks, rather than everyday transactional computing.
Where It Might Be Used - and Current Limits
The company points to entertainment and media archives as an early target, given studios' growing need to preserve large libraries of digital content over decades. Other cited sectors include financial services, logistics, manufacturing, scientific research, and resource exploration. AtlasBase says it is launching Early Access Programs with select partners for both its Molecular Compute and Molecular Data Storage offerings.
It's worth noting that these are early-access, partner-limited programs rather than generally available products, and AtlasBase has not published independent performance benchmarks, pricing, or third-party validation of its scale claims. Molecular storage and DNA-based computation remain emerging fields industry-wide, and questions about synthesis speed, retrieval latency, error rates, and cost per byte at commercial scale are typically where such technologies face their toughest tests. Enterprises evaluating this kind of platform will likely want to see independent benchmarking before treating it as a near-term alternative to tape or cloud archival storage.
- Core technology: CMOS-based DNA synthesis chip (Thalia)
- Claimed scale: 5.6 billion synthesis sites, 700x prior chips
- Status: Early Access Programs with select partners, not general availability